2023 Was a tricky 12 months for the biopharma sector, with quite a few businesses downsizing and restructuring their workforces to stay afloat. There are actually indications of Restoration, as mergers and acquisitions picked up through the pharmaceutical and life sciences market while in the latter Section of 2023 and https://sites.google.com/view/bio-sites/blog